Indications And Dose
Urinary frequency | Urinary urgency | Urge incontinence ▶BY MOUTH ▶Adult: 4 mg once daily, increased if necessary up to 8 mg once daily
PDF page 843
Loading InternPractice…
Drug reference
Urinary frequency | Urinary urgency | Urge incontinence ▶BY MOUTH ▶Adult: 4 mg once daily, increased if necessary up to 8 mg once daily
PDF page 843
DUE TO INTERACTIONS ▶Manufacturer advises max. 4 mg daily with concurrent use of potent inhibitors of CYP3A4; avoid concurrent use in patients who also have hepatic or renal impairment. ▶For dose adjustments with concurrent use of moderate inhibitors of CYP3A4 in patients with hepatic or renal impairment, consult product literature.
PDF page 843
The need for continuing therapy for urinary incontinence should be reviewed every 4–6 weeks until symptoms stabilise, and then every 6–12 months.
PDF page 843
Scottish Medicines Consortium (SMC) decisions SMC No. 480/08 The Scottish Medicines Consortium has advised (July 2008) that fesoterodine (Toviaz ®) is accepted for restricted use within NHS Scotland as a second-line treatment for overactive bladder syndrome.
PDF page 843
→Appendix 1: fesoterodine
PDF page 843
▶Common or very common Diarrhoea. dry eye. gastrointestinal discomfort. insomnia. throat complaints ▶Uncommon Cough. fatigue. gastrointestinal disorders. nasal dryness. taste altered. urinary tract infection. vertigo
PDF page 843
Manufacturer advises avoid—toxicity in animal studies.
PDF page 843
Manufacturer advises avoid—no information available.
PDF page 843
Manufacturer advises caution in mild to moderate impairment; avoid in severe impairment (no information available). Dose adjustments Manufacturer advises increase dose cautiously in mild impairment; maximum 4 mg daily in moderate impairment.
PDF page 843
Dose adjustments Increase dose cautiously if eGFR 30–80 mL/minute/1.73m2; max. 4 mg daily if eGFR less than 30 mL/minute/1.73m2.
PDF page 843
There can be variation in the licensing of different medicines containing the same drug. Modified-release tablet Genito-urinary system CAUTIONARY AND ADVISORY LABELS 3, 25 ▶Toviaz (Pfizer Ltd) Fesoterodine fumarate 4 mg Toviaz 4mg modified-release tablets | 28 tablet P £25.78 DT = £25.78 Fesoterodine fumarate 8 mg Toviaz 8mg modified-release tablets | 28 tablet P £25.78 DT = £25.78 eiiii F 820
PDF page 843
4 mg once daily, increased if necessary up to
First-line fragment. Read the complete Indications and Dose section above.
PDF page 843